Madrigal Pharmaceuticals (MDGL) Common Equity (2010 - 2026)

Madrigal Pharmaceuticals (MDGL) has 17 years of Common Equity data on file, last reported at $543.5 million in Q1 2026.

• On a quarterly basis, Common Equity fell 23.53% year-over-year to $543.5 million in Q1 2026; TTM through Mar 2026 was $543.5 million, a 23.53% decrease from a year earlier, with the FY2025 full-year figure at $602.7 million, down 20.11% from the prior year.
• Common Equity for Q1 2026 stood at $543.5 million, down from $602.7 million in the prior quarter.
• Over the last five years, Common Equity for MDGL reached as high as $857.1 million in Q2 2024 and fell as low as $10.7 million in Q3 2022.
• Historically, Common Equity has averaged $443.3 million across 5 years, with a median of $543.5 million in 2026.
• Across the five-year window, Common Equity slumped 95.46% in 2022 and soared 3392.99% in 2024, its largest moves.
• Year by year, Common Equity stood at $197.4 million in 2022, then jumped by 105.35% to $405.3 million in 2023, then jumped by 86.11% to $754.4 million in 2024, then slipped by 20.11% to $602.7 million in 2025, then slipped by 9.83% to $543.5 million in 2026.
• Per Business Quant data, the three most recent Common Equity figures were $543.5 million in Q1 2026, $602.7 million in Q4 2025, and $625.7 million in Q3 2025.